S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Cyanotech (CYAN) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

CYAN vs. AKAN, SNOA, NMRD, MOTS, GMDA, CPHI, RSLS, CMND, BPTH, and ACON

Should you be buying Cyanotech stock or one of its competitors? The main competitors of Cyanotech include Akanda (AKAN), Sonoma Pharmaceuticals (SNOA), Nemaura Medical (NMRD), Motus GI (MOTS), Gamida Cell (GMDA), China Pharma (CPHI), ReShape Lifesciences (RSLS), Clearmind Medicine (CMND), Bio-Path (BPTH), and Aclarion (ACON). These companies are all part of the "medical" sector.

Cyanotech vs.

Akanda (NASDAQ:AKAN) and Cyanotech (NASDAQ:CYAN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Akanda has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Cyanotech received 128 more outperform votes than Akanda when rated by MarketBeat users.

CompanyUnderperformOutperform
AkandaN/AN/A
CyanotechOutperform Votes
128
63.68%
Underperform Votes
73
36.32%

Cyanotech has higher revenue and earnings than Akanda.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akanda$3.94M0.21-$11.66MN/AN/A
Cyanotech$23.18M0.10-$3.44M-$0.74-0.45

In the previous week, Akanda had 2 more articles in the media than Cyanotech. MarketBeat recorded 3 mentions for Akanda and 1 mentions for Cyanotech. Cyanotech's average media sentiment score of 0.34 beat Akanda's score of 0.00 indicating that Akanda is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akanda
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cyanotech
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akanda
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Cyanotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

1.0% of Akanda shares are held by institutional investors. Comparatively, 24.4% of Cyanotech shares are held by institutional investors. 20.4% of Akanda shares are held by insiders. Comparatively, 25.2% of Cyanotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Akanda has a net margin of 0.00% compared to Akanda's net margin of -20.52%. Cyanotech's return on equity of 0.00% beat Akanda's return on equity.

Company Net Margins Return on Equity Return on Assets
AkandaN/A N/A N/A
Cyanotech -20.52%-30.97%-16.17%

Summary

Akanda beats Cyanotech on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYAN vs. The Competition

MetricCyanotechMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$2.29M$1.34B$4.77B$7.44B
Dividend YieldN/A2.35%2.99%4.00%
P/E Ratio-0.457.86255.7719.15
Price / Sales0.1010.952,414.2285.81
Price / CashN/A171.4147.3635.12
Price / Book0.132.424.594.19
Net Income-$3.44M-$174.77M$104.50M$214.15M

Cyanotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKAN
Akanda
0 of 5 stars
$0.12
flat
N/A-90.8%$1.07M$3.94M0.0046Gap Down
SNOA
Sonoma Pharmaceuticals
2.1501 of 5 stars
$0.15
+7.0%
$3.25
+2,027.0%
-82.9%$2.39M$13.27M-0.169Gap Up
NMRD
Nemaura Medical
1.6757 of 5 stars
$0.08
flat
$2.50
+2,945.1%
-91.0%$2.37M$80,000.00-0.2136Gap Up
MOTS
Motus GI
1.5024 of 5 stars
$0.47
+6.9%
$28.88
+6,089.7%
-99.4%$2.35M$320,000.00-0.0215Positive News
GMDA
Gamida Cell
0.595 of 5 stars
$0.02
flat
$4.75
+31,357.0%
-98.5%$2.33M$1.78M-0.02143Gap Down
CPHI
China Pharma
0 of 5 stars
$0.38
+8.6%
N/A-84.0%$2.50M$7.01M0.00234
RSLS
ReShape Lifesciences
0.3488 of 5 stars
$0.17
+6.1%
$8.00
+4,507.0%
-94.8%$2.28M$8.68M0.0040
CMND
Clearmind Medicine
0 of 5 stars
$1.32
+17.9%
N/A-93.2%$2.24MN/A0.00N/ANews Coverage
BPTH
Bio-Path
1.464 of 5 stars
$3.82
-1.8%
$40.00
+947.1%
-88.4%$2.60MN/A-0.0910Analyst Report
Short Interest ↑
News Coverage
Gap Down
Trading Halted
ACON
Aclarion
0 of 5 stars
$0.31
-3.2%
N/A-97.7%$2.20M$80,000.000.004Short Interest ↑
Gap Up

Related Companies and Tools

This page (NASDAQ:CYAN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners